(IN BRIEF) Scientists at The Institute of Cancer Research, London have identified features in some aggressive cancer cells that may make them vulnerable to ROCK inhibitors, a group of drugs already used to treat glaucoma. The research found relevant markers … Read the full press release
Posted in Business, Education, Healthcare, Non Profit, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acute myeloid leukaemia, aggressive cancer cells, AML, Barts Cancer Institute, Barts Charity, biomarker discovery, breast cancer, Breast Cancer Now, Breast Cancer Now Toby Robins Research Centre, cancer cell biology, Cancer Cell Shape and Gene Patterns May Help Identify Patients Suitable for Glaucoma Drug Trials, cancer research, Cancer Research UK, cancer spread, cell scaffolding, clinical trials, Dr Simon Vincent, drug repurposing, drug sensitivity database, E-Cadherin, epithelial solid tumours, glaucoma drugs, ICR, ICR Study Opens Path Toward Testing ROCK Inhibitors in Personalised Cancer Treatment, invasive border, iScience, Jaume Barcelo, laboratory validation, melanoma, metastasis, metastatic cancer, molecular fingerprint, mouse studies, NFKB, NHS glaucoma treatment, non-epithelial solid tumours, patient biopsies, personalised cancer treatment, Professor Victoria Sanz Moreno, Queen Mary University of London, Rho kinase, ROCK inhibitors, rounded cancer cells, The Institute of Cancer Research London, treatment resistance, tumour growth, tumour inflammation, tumour invasion, tumour samples, UK Research and Innovation, UKRI, Worldwide Cancer Research
(IN BRIEF) Researchers have identified a previously unknown mechanism that helps melanoma cells spread and resist immunotherapy. The study, published in The EMBO Journal, shows that the protein NGFR activates a pathway involving MLC2, increasing tumour invasiveness while contributing to … Read the full press release
Posted in Education, Healthcare, Non Profit, Pharma & Biotech, Science, Spain, United Kingdom
Tagged advanced melanoma, Barts Charity, biomarker, Blocking NGFR May Help Restore Immunotherapy Sensitivity in Melanoma Models, Breast Cancer Now, cancer biology, Cancer Research UK, cancer spread, cancer treatment, CNB-CSIC, combination treatment, experimental drug, Héctor Peinado, ICR, ICR Scientists Help Identify Potential New Target for Resistant Advanced Melanoma, immune checkpoint therapy, immunotherapy resistance, Madrid, melanoma, metastasis, MLC2, myosin II signalling pathway, myosin light chain 2, nerve growth factor receptor, New Research Uncovers Hidden Mechanism Behind Melanoma Spread and Treatment Resistance, NGFR, oncology, preclinical research, skin cancer, Spain, The EMBO Journal, The Institute of Cancer Research, THX-B, tumour invasion, UK Research and Innovation, United Kingdom, University of London, Victoria Sanz-Moreno, Worldwide Cancer Research
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?